FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Sender Gary 		2. Issuer Name and Ticker or Trading Symbol

Nabriva Therapeutics plc [ NBRV ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

1000 CONTINENTAL DRIVE, SUITE 600 		3. Date of Earliest Transaction (MM/DD/YYYY)

1/31/2018
(Street)

KING OF PRUSSIA, PA 19406
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options     (1) 1/31/2018     A      100000         (2) 1/31/2028   Ordinary Shares   100000   $0.00   100000   D    
Restricted Stock Units     (3) 1/31/2018     A      22500         (4) 1/31/2021   Ordinary Shares   22500   $0.00   22500   D    

Explanation of Responses:
(1)  The exercise price is $6.47 per share.
(2)  The option award was granted on January 31, 2018. Vesting began on January 31, 2018 and ends on January 31, 2022. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
(3)  The restricted stock units shall convert into ordinary shares on a one-for-one basis upon vesting of the units.
(4)  Vesting of the restricted stock unit award is subject to U.S. Food and Drug Administration ("FDA") approval of a new drug application ("NDA") for lefamulin. Fifty percent (50%) of the restricted stock unit award will vest upon FDA approval of an NDA for lefamulin, and the remaining fifty percent (50%) of the restricted stock unit award will vest on the one (1) year anniversary of such approval. If the FDA does not approve an NDA for lefamulin within two years of the grant date, the the restricted stock unit award will terminate in full.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Sender Gary
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA, PA 19406

Chief Financial Officer

Signatures
/s/ Robert Crotty, by power of attorney 2/2/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Nabriva Therapeutics Charts.
Nabriva Therapeutics (NASDAQ:NBRV)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Nabriva Therapeutics Charts.